New atypical antipsychotic drug

recently yet another atypical antipsychotic medication has been FDA approved and is commercially available. Lurasidone (Latuda) was approved for the treatment of schizophrenia.  It is claimed to be relatively devoid of weight gain, QT prolongation and metabolic alterations. It does have side effects of sedation, akathesias, parkinsonian symptoms, and agitation. 40 mg once daily is the recommended starting dose.  My own review of data leads to my conclusion that it had little to offer from older drugs. I recommend that the interested reader performa literature search at www.pubmed.gov (search lurasidone) and also read Daniel Carlat's review at "The Carlat Psychiatry Blog"